Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, San Diego and Jersey

Parsippany-Troy Hills, US (HQ)

5 Sylvan Way

San Diego, US

10578 Science Center Dr, Suite 125

San Diego, US

11011 N Torrey Pines Rd

Pacira Pharmaceuticals's revenue was reported to be $69.3 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 69.3 m |

## Gross profit (Q1, 2017) | 44.7 m |

## Gross profit margin (Q1, 2017), % | 65% |

## Net income (Q1, 2017) | (19.9 m) |

## EBIT (Q1, 2017) | (14.1 m) |

## Market capitalization (17-Aug-2017) | 1.4 b |

## Cash (31-Mar-2017) | 109 m |

Pacira Pharmaceuticals's current market capitalization is $1.4 b.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 85.6 m | 197.7 m | 249 m | 276.4 m |

## Revenue growth, % | 131% | 26% | 11% | |

## Cost of goods sold | 54.8 m | 77.4 m | 71.8 m | 77.4 m |

## Gross profit | 30.8 m | 120.2 m | 177.2 m | 198.9 m |

## Gross profit Margin, % | 36% | 61% | 71% | 72% |

## R&D expense | 18.7 m | |||

## General and administrative expense | 106.7 m | |||

## Operating expense total | 138.8 m | 202.8 m | 239.5 m | 202.8 m |

## EBIT | (53.3 m) | (5.2 m) | 9.5 m | (5.2 m) |

## EBIT margin, % | (62%) | (3%) | 4% | (2%) |

## Interest expense | 7.3 m | 8.3 m | 7.7 m | 8.3 m |

## Interest income | 259 k | 382 k | 678 k | 382 k |

## Pre tax profit | (64.4 m) | (13.5 m) | 2.1 m | (13.5 m) |

## Income tax expense | 442 k | (173 k) | (264 k) | (173 k) |

## Net Income | (63.9 m) | (13.7 m) | 1.9 m | (37.9 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 47.2 m | 52 m | 58.3 m | 59.1 m | 62.2 m | 65.5 m | 69.6 m | 68.4 m | 69.3 m |

## Cost of goods sold | 20 m | 20.4 m | 17.6 m | 18.9 m | 15.9 m | 20.3 m | 23.1 m | 43.2 m | 24.6 m |

## Gross profit | 27.2 m | 31.7 m | 40.7 m | 40.2 m | 46.3 m | 45.2 m | 46.6 m | 25.2 m | 44.7 m |

## Gross profit Margin, % | 58% | 61% | 70% | 68% | 74% | 69% | 67% | 37% | 65% |

## R&D expense | 5.2 m | 4.4 m | 6 m | 3.6 m | 5.9 m | 9.5 m | 9.4 m | 9.8 m | 16.6 m |

## General and administrative expense | 24.8 m | 28.2 m | 31.4 m | 34.8 m | 35.3 m | 38 m | 43.7 m | 36.3 m | 42.1 m |

## Operating expense total | 30.1 m | 32.6 m | 37.4 m | 38.4 m | 41.2 m | 47.5 m | 53 m | 46.1 m | 58.8 m |

## EBIT | (2.8 m) | (985 k) | 3.3 m | 1.8 m | 5.1 m | (2.3 m) | (6.4 m) | (20.9 m) | (14.1 m) |

## EBIT margin, % | (6%) | (2%) | 6% | 3% | 8% | (3%) | (9%) | (31%) | (20%) |

## Interest expense | (2.1 m) | (2 m) | (2 m) | (1.9 m) | (1.9 m) | (1.9 m) | (1.7 m) | (1.6 m) | (2.6 m) |

## Interest income | 61 k | 134 k | 155 k | 177 k | 171 k | 252 k | 324 k | 346 k | 514 k |

## Pre tax profit | (5 m) | (3 m) | 1.3 m | 47 k | 3.4 m | (3.8 m) | (7.9 m) | (22.1 m) | (19.8 m) |

## Income tax expense | (52 k) | (39 k) | (281 k) | (32 k) | (58 k) | (36 k) | (30 k) | ||

## Net Income | (16.5 m) | (19.5 m) | 1.3 m | 1.3 m | 4.4 m | (3.9 m) | (11.8 m) | (34 m) | (19.9 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 12.5 m | 37.5 m | 57 m | 35.9 m |

## Accounts Receivable | 14.6 m | 22.4 m | 25.9 m | 29.9 m |

## Inventories | 15.6 m | 29.3 m | 6.1 m | 31.3 m |

## Current Assets | 106.8 m | 214.3 m | 252.6 m | 243.1 m |

## Goodwill | 10.3 m | 23.8 m | 30.9 m | 46.7 m |

## Total Assets | 169.8 m | 326.1 m | 389.6 m | 391.5 m |

## Accounts Payable | 3.1 m | 6.8 m | 8.7 m | 7.5 m |

## Current Liabilities | 121.9 m | 140 m | 151.7 m | 44.8 m |

## Total Liabilities | 172.5 m | |||

## Additional Paid-in Capital | 337.6 m | 481.3 m | 526.7 m | 565.2 m |

## Retained Earnings | (296.4 m) | (310.1 m) | (308.3 m) | (346.2 m) |

## Total Equity | 41.2 m | 218.4 m | 219 m | |

## Financial Leverage | 4.1 x | 1.8 x | 1.8 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 108.2 m | 17.8 m | 40.9 m | 32.7 m | 30.5 m | 35 m | 25.3 m | 24.4 m | 109 m |

## Accounts Receivable | 20.5 m | 20.5 m | 24.5 m | 24.3 m | 25.9 m | 25.9 m | 28.7 m | 26.8 m | 27.7 m |

## Inventories | 19.2 m | 23.7 m | 36.3 m | 48.8 m | 56.1 m | 63.7 m | 60.9 m | 37.5 m | 30.3 m |

## Current Assets | 208.9 m | 199.2 m | 248.6 m | 258 m | 235.4 m | 448 m | |||

## Goodwill | 12.5 m | 22 m | 67.2 m | 77.8 m | 86.3 m | 32.8 m | 42.8 m | 44.7 m | 48.8 m |

## Total Assets | 292.1 m | 305.4 m | 2.4 m | 2.3 m | 2.6 m | 391.2 m | 400.7 m | 381.2 m | 600 m |

## Accounts Payable | 3.1 m | 7.7 m | 10.5 m | 4.6 m | 7.3 m | 9.4 m | |||

## Current Liabilities | 129.5 m | 135.2 m | 136.5 m | 145.5 m | 145.4 m | 146.1 m | 150.4 m | 146.8 m | 45.6 m |

## Additional Paid-in Capital | 460.9 m | 471 m | 36 k | 37 k | 37 k | 538.2 m | 548.3 m | 556.4 m | 637.1 m |

## Retained Earnings | (312.9 m) | (315.9 m) | 492.9 m | 504.1 m | 514.8 m | (312.1 m) | (320.1 m) | (342.3 m) | (366.4 m) |

## Total Equity | (27 k) | (29 k) | 226.2 m | 228.4 m | 214.1 m | 270.6 m | |||

## Financial Leverage | -83.4 x | -89.5 x | 1.7 x | 1.8 x | 1.8 x | 2.2 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (63.9 m) | (13.7 m) | 1.9 m | (13.7 m) |

## Depreciation and Amortization | 5.7 m | |||

## Accounts Receivable | (10 m) | (7.8 m) | (3.5 m) | (7.8 m) |

## Inventories | (3.5 m) | (14 m) | (32 m) | |

## Accounts Payable | 10.2 m | 14.3 m | 9.9 m | |

## Cash From Operating Activities | (43.2 m) | 25.5 m | 29 m | 26.6 m |

## Purchases of PP&E | (12.8 m) | |||

## Cash From Investing Activities | (43.6 m) | (119.3 m) | (20.2 m) | (120.4 m) |

## Long-term Borrowings | (27.5 m) | |||

## Cash From Financing Activities | 89.2 m | 118.9 m | 10.7 m | 118.9 m |

## Income Taxes Paid | 34 k | 195 k | 34 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (16.5 m) | (19.5 m) | 1.3 m | 1.3 m | 4.4 m | (3.9 m) | (11.8 m) | (34 m) | (19.9 m) |

## Depreciation and Amortization | 4.9 m | ||||||||

## Accounts Receivable | (6 m) | (5.9 m) | (2.1 m) | (1.9 m) | (3.6 m) | (46 k) | (2.8 m) | (910 k) | 2.2 m |

## Inventories | (3.6 m) | (8.1 m) | (7 m) | ||||||

## Accounts Payable | 5.2 m | 10.2 m | (4.3 m) | 5 m | 2 m | (6.2 m) | (8.7 m) | ||

## Cash From Operating Activities | 12.5 m | 493 k | 9.1 m | 12 m | (3.1 m) | 4.4 m | 16.1 m | 6 k | |

## Cash From Investing Activities | (21.6 m) | (123.4 m) | (1.2 m) | (20.6 m) | (27.5 m) | (21.9 m) | (41.5 m) | (54.8 m) | (143.8 m) |

## Long-term Borrowings | (117.7 m) | ||||||||

## Cash From Financing Activities | 113.8 m | 116.1 m | 4 m | 6.7 m | 8.5 m | 3 m | 5.4 m | 6.2 m | 216.9 m |

## Interest Paid | 2.4 m | ||||||||

## Income Taxes Paid | 160 | 159 | 199 | 142 k | 241 k | 253 k |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 137.7 k |

## Financial Leverage | 2.2 x |